UMC 119 01
Alternative Names: hUC-MSCs; Human umbilical cord derived-mesenchymal stem cells - Meridigen Biotech; UMC119-01Latest Information Update: 28 Dec 2024
At a glance
- Originator Meridigen Biotech
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bronchopulmonary dysplasia
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Bronchopulmonary-dysplasia(In infants) in Taiwan (Parenteral)
- 15 Dec 2022 UMC 119 01 is still in phase I trials for Bronchopulmonary dysplasia (In infants) in Taiwan (Parenteral) (Meridigen biotech pipeline, December 2022)
- 26 Oct 2018 Phase-I clinical trials in Bronchopulmonary dysplasia (In infants) in Taiwan (Parenteral) (NCT03631420)